Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
1. A method of inhibiting tumor growth in a subject comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) for inhibiting tumor growth to the subject.
2. A method of increasing an anti-tumor immune response comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) to a subject in need thereof.
3. A method of treating a tumor in a subject comprising administering to the subject an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari).
4. The method of claim 3 , wherein the A2A receptor inhibitor is SCH58261.
5. The method of claim 3 , wherein the anti-CD73 antibody or antigen-binding fragment thereof and the A2Ari are administered concurrently.
6. The method of claim 3 , wherein the anti-CD73 antibody or antigen-binding fragment thereof is administered prior to the A2Ari.
7. The method of claim 3 , wherein the A2Ari is administered prior to the anti-CD73 antibody or antigen-binding fragment thereof.
8. The method of claim 3 , wherein the tumor is a lung cancer.
9. The method of claim 3 , wherein said method results in an increase in overall survival as compared to the administration of any one of the anti-CD73 antibody or the A2Ari alone.
10. The method of claim 3 , wherein the said method induces or increases a tumor-specific immune response.
11. The method of claim 3 , wherein the said method reduces the immunosuppressive effects of a AMP/CD73/adenosine pathway.
12. The method of claim 3 , wherein the said method reduces metastasis or reduces the propensity of the tumor to metastasize relative to the administration of either the anti-CD73 antibody or the A2Ari alone.
13. The method of claim 3 , wherein the said method reduces the number of metastases within the subject.
14. The method of claim 3 , wherein the subject is a human patient.
15. The method of claim 3 , wherein the tumor is a CD73 overexpressing tumor.